Better dosing strategy for Crohn's disease treatment in young patients

This trial is testing whether a precision-dosing approach to infliximab—a medication that reduces inflammation—works better than the standard dosing schedule for children and young adults with newly diagnosed Crohn's disease. The precision approach uses blood tests and other markers to personalize your dose, aiming to help your bowel heal completely. The goal is to see if this personalized strategy achieves better healing and prevents future complications.

Many patients with Crohn's disease respond well to this medication, but not everyone gets the same benefit from the same dose. Research shows that patients who reach high enough medication levels in their blood tend to heal better and have fewer problems. This trial tests whether actively adjusting doses to reach personalized targets—rather than using a one-size-fits-all approach—gives more patients that deeper, lasting healing.